MEI Pharma Management
Management criteria checks 2/4
MEI Pharma's CEO is David Urso, appointed in Jun 2023, has a tenure of less than a year. total yearly compensation is $2.10M, comprised of 25.8% salary and 74.2% bonuses, including company stock and options. directly owns 0.037% of the company’s shares, worth $8.21K. The average tenure of the management team and the board of directors is 1.5 years and 3.5 years respectively.
Key information
David Urso
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 25.8% |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11
MEI Pharma EPS beats by $0.01, beats on revenue
Feb 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$20m |
| Sep 30 2023 | n/a | n/a | US$41m |
| Jun 30 2023 | US$2m | US$541k | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | US$2m | US$517k | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | n/a | n/a | -US$64m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | US$2m | US$492k | -US$41m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | n/a | n/a | -US$31m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | US$1m | US$460k | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | n/a | n/a | -US$38m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | US$1m | US$426k | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | n/a | n/a | -US$28m |
| Sep 30 2018 | n/a | n/a | -US$46m |
| Jun 30 2018 | US$1m | US$390k | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$2m |
| Jun 30 2017 | US$671k | US$375k | US$3m |
Compensation vs Market: David's total compensation ($USD2.10M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Urso (59 yo)
less than a year
Tenure
US$2,101,058
Compensation
Mr. David M. Urso, Esq., JD, serves as Chief Executive Officer and President at MEI Pharma, Inc. since June 2, 2023 and had been its Senior Vice President of Corporate Development from March 2014 to July 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.10m | 0.037% $ 8.2k | |
| Chief Medical Officer | 8.1yrs | US$846.66k | 0.022% $ 4.8k | |
| CFO & Corporate Secretary | less than a year | no data | no data | |
| Senior Vice President of Operations & Quality | less than a year | no data | no data | |
| Vice President of Legal Affairs | 1.3yrs | no data | no data | |
| Chief People Officer | 1.8yrs | no data | no data | |
| Strategic Advisor | 12.8yrs | US$755.98k | 0% $ 0 | |
| Senior Vice President of Corporate Affairs | 2.9yrs | no data | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Management: MEIP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$2.10m | 0.037% $ 8.2k | |
| Independent Non-Executive Director | 6.2yrs | US$99.20k | 0.028% $ 6.2k | |
| Independent Non-Executive Director | 10.8yrs | US$111.20k | 0% $ 0 | |
| Independent Non-Executive Director | 11.2yrs | US$144.60k | 0.0075% $ 1.7k | |
| Independent Non-Executive Chair | 12.5yrs | US$119.20k | 0.083% $ 18.5k | |
| Independent Non-Executive Director | less than a year | no data | 0.019% $ 4.2k | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
3.5yrs
Average Tenure
56.5yo
Average Age
Experienced Board: MEIP's board of directors are considered experienced (3.5 years average tenure).